Gout and type 2 diabetes have a mutual inter-dependent effect on genetic risk factors and higher incidences

Rheumatology

Volumn 51, Issue 4, 2012, Pages 715-720

  Lai, Han Ming ^a   Chen, Chung Jen ^a   Su, Ben Yu Jih ^a   Chen, Ying Chou ^a   Yu, Shan Fu ^a   Yen, Jeng Hsien ^b   Hsieh, Ming Chia ^c   Cheng, Tien Tsai ^a   Chang, Shun Jen ^d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Early onset; Genetic epidemiology; Genetic risk factor; Genome wide analysis study; Gout; Incidence; Male; National health insurance; Outpatient records; Type 2 diabetes

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GOUT; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARDIZED INCIDENCE RATIO;

ADULT; AGE OF ONSET; AGED; COMORBIDITY; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GOUT; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TAIWAN;

EID: 84863387745     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker373     Document Type: Article

References (44)

1. Rothenbacher D, Primatesta P, Ferreira A et al. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology 2011;50:973-81.
2. Pillinger MH, Goldfarb DS, Keenan RT. Gout and its comorbidities. Bull NYU Hosp Jt Dis 2010;68:199-203.
3. Yoo HG, Lee SI, Chae HJ et al. Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis. Rheumatol Int 2011;31:485-91.
4. Suppiah R, Dissanayake A, Dalbeth N. High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors. N Z Med J 2008;121:43-50.
5. Rodriguez G, Soriano LC, Choi HK. Impact of diabetes against the future risk of developing gout. Ann Rheum Dis 2010;69:2090-4.
6. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 1998;57:509-10.
7. Lee J, Sparrow D, Vokonas PS et al. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 1995;142:288-94.
8. Rathmann W, Funkhouser E, Dyer AR et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998;8:250-61.
9. Vazquez-Mellado J, Garcia CG, Vazquez SG et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004;10:105-9.
10. Choi HK, Ford ES, Li C et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57:109-15.
11. Krishnan E, Baker JF, Furst DE et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54: 2688-96.
12. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116:894-900.
13. Choi HK, Atkinson K, Karlson EW et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-103.
14. Shadick NA, Kim R, Weiss S et al. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J Rheumatol 2000;27:1708-12.
15. Chang SJ, Ko YC, Wang TN et al. High prevalence of gout and related risk factors in Taiwan's Aborigines. J Rheumatol 1997;24:1364-9.
16. Harrold LR, Yood RA, Mikuls TR et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 2006;65:1368-72.
17. Chang SJ, Chang JG, Chen CJ et al. Identification of a new single nucleotide substitution on the hypoxanthine-guanine phosphoribosyltransferase gene HPRT(Tsou) from a Taiwanese aboriginal family with severe gout. J Rheumatol 1999;26:1802-7.
18. Wu CH, Lai HM, Yang MC et al. Identification of a new single-nucleotide mutation on the hypoxanthine-guanine phosphoribosyltransferase gene from 983 cases with gout in Taiwan. J Rheumatol 2007;34:794-7.
19. Graessler J, Graessler A, Unger S et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006;54:292-300.
20. Wang WH, Chang SJ, Wang TN et al. Complex segregation and linkage analysis of familial gout in Taiwanese aborigines. Arthritis Rheum 2004;50:242-6.
21. Stiburkova B, Majewski J, Sebesta I et al. Familial juvenile hyperuricemic nephropathy: localization of the gene on chromosome 16p11.2-and evidence for genetic heterogeneity. Am J Hum Genet 2000;66:1989-94.
22. Chang SJ, Tsai PC, Chen CJ et al. The polymorphism -863C/A in tumour necrosis factor-alpha gene contributes an independent association to gout. Rheumatology 2007; 46:1662-6.
23. Chang SJ, Tsai MH, Ko YC et al. The cyclic GMP-dependent protein kinase II gene associates with gout disease: identified by genome-wide analysis and case-control study. Ann Rheum Dis 2009;68:1213-9.
24. Chang SJ, Chen CJ, Tsai FC et al. Associations between gout tophus and polymorphisms 869T/C and -509C/T in transforming growth factor beta1 gene. Rheumatology 2008;47:617-21.
25. Greenland S, Rothman KJ. Introduction to stratified analysis. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008:252-82.
26. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6.
27. Roubenoff R, Klag MJ, Mead LA et al. Incidence and risk factors for gout in white men. JAMA 1991;266: 3004-7.
28. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000;27:1501-5.
29. Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract 2003;61(Suppl. 1): S9-18.
30. Zhou H, Tan KC, Shiu SW et al. Determinants of leukocyte adenosine triphosphate-binding cassette transporter G1 gene expression in type 2 diabetes mellitus. Metabolism 2008;57:1135-40.
31. Chen H, Jawahar S, Qian Y et al. Missense polymorphism in the human carboxypeptidase E gene alters enzymatic activity. Hum Mutat 2001;18:120-31.
32. Tsai FJ, Yang CF, Chen CC et al. A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet 2010;6: e1000847.
33. Wang Z, Hall SD, Maya JF et al. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003;55:77-85.
34. Becker ML, Visser LE, van Schaik RH et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009;9:242-7.
35. Kanazawa A, Tsukada S, Sekine A et al. Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet 2004;75:832-43.
36. Salpea KD, Gable DR, Cooper JA et al. The effect of WNT5B IVS3C>G on the susceptibility to type 2 diabetes in UK Caucasian subjects. Nutr Metab Cardiovasc Dis 2009;19:140-5.
37. Jacobelli S, Arteaga A, Bidegain F. Cholesterol distribution among lipoprotein fractions in patients with gout and normal controls. J Rheumatol 1986;13:774-7.
38. Jiao S, Kameda K, Matsuzawa Y et al. Hyperlipoproteinaemia in primary gout: hyperlipoproteinaemic phenotype and influence of alcohol intake and obesity in Japan. Ann Rheum Dis 1986;45: 308-13.
39. von Eckardstein A, Schulte H, Assmann G. Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Munster. J Clin Endocrinol Metab 2000;85:3101-8.
40. Lawn RM, Wade DP, Garvin MR et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999;104:R25-31.
41. Tanaka AR, Ikeda Y, Abe-Dohmae S et al. Human ABCA1 contains a large amino-terminal extracellular domain homologous to an epitope of Sjogren's syndrome. Biochem Biophys Res Commun 2001;283: 1019-25.
42. Brunham LR, Kruit JK, Pape TD et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007;13: 340-7.
43. von Eckardstein A, Sibler RA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011;22: 26-32.
44. Saely CH, Eber B, Pfeiffer KP et al. Low serum LDL cholesterol in patients with type 2 diabetes: an analysis on two different patient populations. Int J Cardiol 2010;144: 394-8.